An update on atrial fibrillation in 2014

From pathophysiology to treatment

R. Ferrari, M. Bertini, C. Blomstrom-Lundqvist, D. Dobrev, P. Kirchhof, C. Pappone, U. Ravens, J. Tamargo, L. Tavazzi, G. G. Vicedomini

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Atrial fibrillation (AF) is the most frequently encountered cardiac arrhythmia. The trigger for initiation of AF is generally an enhanced vulnerability of pulmonary vein cardiomyocyte sleeves to either focal or re-entrant activity. The maintenance of AF is based on a "driver" mechanism in a vulnerable substrate. Cardiac mapping technology is providing further insight into these extremely dynamic processes. AF can lead to electrophysiological and structural remodelling, thereby promoting the condition. The management includes prevention of stroke by oral anticoagulation or left atrial appendage (LAA) occlusion, upstream therapy of concomitant conditions, and symptomatic improvement using rate control and/or rhythm control. Nonpharmacological strategies include electrical cardioversion and catheter ablation. There are substantial geographical variations in the management of AF, though European data indicate that 80% of patients receive adequate anticoagulation and 79% adequate rate control. High rates of morbidity and mortality weigh against perceived difficulties in management. Clinical research and growing experience are helping refine clinical indications and provide better technical approaches. Active research in cardiac electrophysiology is producing new antiarrhythmic agents that are reaching the experimental clinical arena, inhibiting novel ion channels. Future research should give better understanding of the underlying aetiology of AF and identification of drug targets, to help the move toward patient-specific therapy.

Original languageEnglish
Pages (from-to)22-29
Number of pages8
JournalInternational Journal of Cardiology
Volume203
DOIs
Publication statusPublished - Jan 15 2016

Fingerprint

Atrial Fibrillation
Therapeutics
Cardiac Electrophysiology
Atrial Appendage
Electric Countershock
Catheter Ablation
Pulmonary Veins
Ion Channels
Research
Cardiac Myocytes
Cardiac Arrhythmias
Stroke
Maintenance
Technology
Morbidity
Mortality
Pharmaceutical Preparations

Keywords

  • Ablation
  • Atrial fibrillation
  • Drug development
  • Pathophysiology
  • Treatments

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Ferrari, R., Bertini, M., Blomstrom-Lundqvist, C., Dobrev, D., Kirchhof, P., Pappone, C., ... Vicedomini, G. G. (2016). An update on atrial fibrillation in 2014: From pathophysiology to treatment. International Journal of Cardiology, 203, 22-29. https://doi.org/10.1016/j.ijcard.2015.10.089

An update on atrial fibrillation in 2014 : From pathophysiology to treatment. / Ferrari, R.; Bertini, M.; Blomstrom-Lundqvist, C.; Dobrev, D.; Kirchhof, P.; Pappone, C.; Ravens, U.; Tamargo, J.; Tavazzi, L.; Vicedomini, G. G.

In: International Journal of Cardiology, Vol. 203, 15.01.2016, p. 22-29.

Research output: Contribution to journalArticle

Ferrari, R, Bertini, M, Blomstrom-Lundqvist, C, Dobrev, D, Kirchhof, P, Pappone, C, Ravens, U, Tamargo, J, Tavazzi, L & Vicedomini, GG 2016, 'An update on atrial fibrillation in 2014: From pathophysiology to treatment', International Journal of Cardiology, vol. 203, pp. 22-29. https://doi.org/10.1016/j.ijcard.2015.10.089
Ferrari, R. ; Bertini, M. ; Blomstrom-Lundqvist, C. ; Dobrev, D. ; Kirchhof, P. ; Pappone, C. ; Ravens, U. ; Tamargo, J. ; Tavazzi, L. ; Vicedomini, G. G. / An update on atrial fibrillation in 2014 : From pathophysiology to treatment. In: International Journal of Cardiology. 2016 ; Vol. 203. pp. 22-29.
@article{db337243d418461a9c05692a74e72009,
title = "An update on atrial fibrillation in 2014: From pathophysiology to treatment",
abstract = "Atrial fibrillation (AF) is the most frequently encountered cardiac arrhythmia. The trigger for initiation of AF is generally an enhanced vulnerability of pulmonary vein cardiomyocyte sleeves to either focal or re-entrant activity. The maintenance of AF is based on a {"}driver{"} mechanism in a vulnerable substrate. Cardiac mapping technology is providing further insight into these extremely dynamic processes. AF can lead to electrophysiological and structural remodelling, thereby promoting the condition. The management includes prevention of stroke by oral anticoagulation or left atrial appendage (LAA) occlusion, upstream therapy of concomitant conditions, and symptomatic improvement using rate control and/or rhythm control. Nonpharmacological strategies include electrical cardioversion and catheter ablation. There are substantial geographical variations in the management of AF, though European data indicate that 80{\%} of patients receive adequate anticoagulation and 79{\%} adequate rate control. High rates of morbidity and mortality weigh against perceived difficulties in management. Clinical research and growing experience are helping refine clinical indications and provide better technical approaches. Active research in cardiac electrophysiology is producing new antiarrhythmic agents that are reaching the experimental clinical arena, inhibiting novel ion channels. Future research should give better understanding of the underlying aetiology of AF and identification of drug targets, to help the move toward patient-specific therapy.",
keywords = "Ablation, Atrial fibrillation, Drug development, Pathophysiology, Treatments",
author = "R. Ferrari and M. Bertini and C. Blomstrom-Lundqvist and D. Dobrev and P. Kirchhof and C. Pappone and U. Ravens and J. Tamargo and L. Tavazzi and Vicedomini, {G. G.}",
year = "2016",
month = "1",
day = "15",
doi = "10.1016/j.ijcard.2015.10.089",
language = "English",
volume = "203",
pages = "22--29",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - An update on atrial fibrillation in 2014

T2 - From pathophysiology to treatment

AU - Ferrari, R.

AU - Bertini, M.

AU - Blomstrom-Lundqvist, C.

AU - Dobrev, D.

AU - Kirchhof, P.

AU - Pappone, C.

AU - Ravens, U.

AU - Tamargo, J.

AU - Tavazzi, L.

AU - Vicedomini, G. G.

PY - 2016/1/15

Y1 - 2016/1/15

N2 - Atrial fibrillation (AF) is the most frequently encountered cardiac arrhythmia. The trigger for initiation of AF is generally an enhanced vulnerability of pulmonary vein cardiomyocyte sleeves to either focal or re-entrant activity. The maintenance of AF is based on a "driver" mechanism in a vulnerable substrate. Cardiac mapping technology is providing further insight into these extremely dynamic processes. AF can lead to electrophysiological and structural remodelling, thereby promoting the condition. The management includes prevention of stroke by oral anticoagulation or left atrial appendage (LAA) occlusion, upstream therapy of concomitant conditions, and symptomatic improvement using rate control and/or rhythm control. Nonpharmacological strategies include electrical cardioversion and catheter ablation. There are substantial geographical variations in the management of AF, though European data indicate that 80% of patients receive adequate anticoagulation and 79% adequate rate control. High rates of morbidity and mortality weigh against perceived difficulties in management. Clinical research and growing experience are helping refine clinical indications and provide better technical approaches. Active research in cardiac electrophysiology is producing new antiarrhythmic agents that are reaching the experimental clinical arena, inhibiting novel ion channels. Future research should give better understanding of the underlying aetiology of AF and identification of drug targets, to help the move toward patient-specific therapy.

AB - Atrial fibrillation (AF) is the most frequently encountered cardiac arrhythmia. The trigger for initiation of AF is generally an enhanced vulnerability of pulmonary vein cardiomyocyte sleeves to either focal or re-entrant activity. The maintenance of AF is based on a "driver" mechanism in a vulnerable substrate. Cardiac mapping technology is providing further insight into these extremely dynamic processes. AF can lead to electrophysiological and structural remodelling, thereby promoting the condition. The management includes prevention of stroke by oral anticoagulation or left atrial appendage (LAA) occlusion, upstream therapy of concomitant conditions, and symptomatic improvement using rate control and/or rhythm control. Nonpharmacological strategies include electrical cardioversion and catheter ablation. There are substantial geographical variations in the management of AF, though European data indicate that 80% of patients receive adequate anticoagulation and 79% adequate rate control. High rates of morbidity and mortality weigh against perceived difficulties in management. Clinical research and growing experience are helping refine clinical indications and provide better technical approaches. Active research in cardiac electrophysiology is producing new antiarrhythmic agents that are reaching the experimental clinical arena, inhibiting novel ion channels. Future research should give better understanding of the underlying aetiology of AF and identification of drug targets, to help the move toward patient-specific therapy.

KW - Ablation

KW - Atrial fibrillation

KW - Drug development

KW - Pathophysiology

KW - Treatments

UR - http://www.scopus.com/inward/record.url?scp=84952658130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952658130&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2015.10.089

DO - 10.1016/j.ijcard.2015.10.089

M3 - Article

VL - 203

SP - 22

EP - 29

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

ER -